Novartis Ag (NYSE: NVS)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Novartis Ag Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novartis Ag Company Info
Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.
News & Analysis
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.
These CRISPR stocks could be big winners for patient investors.
This big pharma company pays a market-topping dividend to shareholders.
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
You're getting a lot of bang for your buck with these stocks.
Novartis' product portfolio and pipeline bode well for its future.
These stocks are all trading close to their 52-week lows.
Whether you're looking for dividends or growth, Novartis and Paramount Global could be viable options for you.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/28/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
We examine three biotech companies' past performances and future outlooks.
Here’s how CAR-T therapies did in their first full year on the market.
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.
Earnings Transcripts
NVS earnings call for the period ending December 31, 2022.
NVS earnings call for the period ending September 30, 2022.
NVS earnings call for the period ending June 30, 2022.
NVS earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.